Peroral and peroral and then congenital acquisition are the two primary routes by which Toxoplasma gondii is acquired in nature and are the first steps in the pathogenesis of disease caused by this parasite. For example, T. gondii is most often acquired perorally by older children and adults. In most instances, it causes no symptoms or self-limited illness initially and then encysts and becomes latent. In immunocompromised individuals, life-threatening toxoplasmosis usually is caused by recrudescence of a latent infection (19) . Congenital Toxoplasma infection is transplacentally transmitted to the fetus when a mother develops a primary Toxoplasma infection acquired perorally during gestation: T. gondii then causes significant eye, ear, or brain damage or systemic illness in utero or later in life (20) . Therefore, we developed a mouse model of peroral (15) and congenital Toxoplasma infection to facilitate study of immune mechanisms that confer protection against toxoplasmosis.
Humoral and cell-mediated immunity were studied because administration of Toxoplasma antigens enhanced survival after parenteral Toxoplasma challenge (10, 22) in the presence of specific Toxoplasma antibody (10) . Such antibodies, with complement, kill extracellular T. gondii (3) and enhance phagocytosis (6) . Also, activated macrophages inhibit or kill T. gondii (16) . The purpose of the present study was to determine whether administration of Toxoplasma antigens which induce such T. gondii-specific antibody and/or administration of heat-killed Propionibacterium acnes, which activates macrophages to inhibit or kill T. gondii, contribute to protection against initial peroral or peroral then congenital acquisition of T. gondii.
MATERIALS AND METHODS
Mice. Twenty-gram Swiss Webster female mice were obtained from Harlan-Sprague Dawley, Inc., Indianapolis, Ind.
T. gondii strains. T. gondii RH was maintained and used for antigen preparation (10, 15) and in vitro challenge of peritoneal macrophages (16) as previously described. T. * Corresponding author. gondii Me49 was provided by M. Lunde, National Institutes of Health, Bethesda, Md. For maintenance of strain Me49, a suspension of brain containing 100 cysts was injected intraperitoneally into Swiss Webster mice. Me49 cysts used for experimental infection were from intraperitoneal passage 7 to 9 and were used within 6 to 24 weeks after infection.
Immunization with Toxoplasma lysate antigens. Toxoplasma lysate antigens were prepared as previously de- scribed (10, 15) . The amount of protein was determined (11) , and the antigen preparation was stored at -20°C. The antigen preparation was diluted in phosphate-buffered saline to a concentration of 1,000 p,g per dose at the time of inoculation. To produce high titers of specific Toxoplasma antibody, mice were immunized intramuscularly two or three times at 2-to 3-week intervals with Toxoplasma lysate antigens. Volumes of 0.1 to 0.2 ml containing 1,000 ,ug of antigen were used for the immunizations. Age-matched controls received phosphate-buffered saline (pH 7.4) intramuscularly. Experiments were initiated when the serum antibody titers in the Sabin-Feldman dye test (3) were .1:1,024.
Inoculation of mice to produce activated macrophages. On day 3 of gestation, mice received 0.1 ml containing 700 ,ug of heat-killed P. acnes antigens (Burroughs Wellcome Co., Research Triangle Park, N.C.) intravenously to activate peritoneal macrophages. Nonpregnant mice received 0.1 ml of P. acnes intravenously 8 or 15 days before study of their peritoneal macrophages.
Breeding. Female mice from each treatment group were caged for 16 h with male mice. Those mice with vaginal plugs were caged individually thereafter.
Peroral challenge. Brain tissue from mice chronically infected with T. gondii Me49 was diluted to contain 200 cysts per 0.5 ml, of saline. A 0.5-ml portion of this suspension was administered intragastrically with an 18-gauge intubation needle (Popper and Son, New Hyde Park, N.Y.) as described previously (15) . One hundred percent of adult mice that receive T. gondii perorally in this manner become infected with T. gondii (15 Sabin-Feldman dye test. The Sabin-Feldman dye test was performed as previously described (3).
Macrophage microbicidal capacity. Peritoneal cells were obtained as previously described (16) . After being harvested, the cells were suspended at a concentration of 4 x 106 cells per ml in medium 199 (GIBCO Laboratories, Grand Island, N.Y.) that contained 10% fetal calf serum, 100 U of penicillin per ml, 100 pug of streptomycin per ml, and 2 mM glutamine (M199-FCS).
Macromethod. Portions (0.5 ml) of the cell suspension were placed into wells of four-chamber Lab-Teks (Miles Scientific, Div. Miles Laboratories, Inc., Naperville, III.). After 1 to 3 h, nonadherent cells were removed and cultures were washed with Hanks balanced salt solution (GIBCO). The cultures were then challenged with T. gondii RH as previously described (18) . Briefly, 0.5 ml of M199-FCS that contained 2 x 106 tachyzoites of T. gondii RH was placed on the adherent peritoneal exudate cells in each well. After 1 h, the cultures were washed with Hanks balanced salt solution and 1 ml of M199-FCS was placed on each of the cultures. The cultures were maintained in M199-FCS for 1 or 18 to 20 h after infection and then fixed in aminoacridine and stained with Giemsa solution. The percent infected cells, mean number of T. gondii per vacuole, and mean number of cells per field (magnification, x400) were determined as described previously (17) .
Micromethod. Portions (0.1 ml) of the cell suspension were placed into wells of 96-well, 0.38-cm2 Linbro plates (Linbro Scientific Inc.). After 1 to 3 h, the cultures were challenged with T. gondii RH as previously described (12) . Briefly, 0.1 ml of M199-FCS that contained 4 x 105 tachyzoites of T. gondii was added to each well containing the peritoneal exudate cells. One hour after the challenge with T. gondii, 25 RI of M199 containing 2.5 piCi of [5,6-3H] uracil (specific activity, 40 to 60 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) was added and the cultures were incubated for an additional 20 h. Cells were dislodged by alternating vigorous washing and aspiration with isotonic saline and collected on glass filters (934-Ah; Whatman, Inc., Clifton, N.J.) by using a multiple automated sample harvester (MASH II; M.A. Bioproducts, Walkersville, Md.). The filters were dried, and the radioactivity in the material retained by the filters was counted in a liquid scintillation spectrophotometer (17) .
Statistics. Statistical significance of differences between all groups and their controls was determined by chi-square analysis using a two-by-two contingency table, by Student's t test, or by analysis of variance.
RESULTS
Effect of Toxoplasma antigens and P. acnes treatment on macrophage microbicidal capacity. The administration of Toxoplasma antigens did not activate peritoneal macrophages. Data from experiments which demonstrate that macrophages obtained from mice with antibody titers to T. gondii 2 1:1,024 did not have enhanced microbicidal capacity against T. gondii are presented in Table 1 . The P. acnes treatment enhanced the microbicidal capacity of peritoneal macrophages (Table 1 ). For example, P. acnes treatment resulted in a reduction in the mean number of T. gondii per vacuole 20 h after in vitro challenge and a reduction in tritiated uracil uptake by intracellular T. gondii. There were no differences in the microbicidal capacities of activated macrophages from pregnant or nonpregnant mice, and differences between controls and mice that received P. acnes were significant (P < 0.01) ( Table 1) . Macrophages obtained from pregnant and nonpregnant mice that received P. acnes and had substantial titers of Toxoplasma antibody also had enhanced microbicidal capacity against T. gondii (Table 1) . For example, there were one to two T. gondii tachyzoites per vacuole in macrophages from the treated mice, whereas macrophages from control mice had five to seven T. gondii tachyzoites per vacuole (Table 1) . Differences in uracil uptake between controls and mice with Toxoplasma antibody and activated macrophages also were significant (P < 0.01).
Effect of Toxoplasma lysate antigens and P. acnes on serum antibody titer to T. gondii. Intramuscular administration of 1,000 pLg of Toxoplasma lysate antigens stimulated the production of specific antibody titers measured by the SabinFeldman dye test 2 1:1,024 in all mice used in the experiments. Intravenously administered P. acnes did not induce specific antibody to T. gondii (n = 12 mice; titer of antibody in Sabin-Feldman dye test = 0).
Effect of treatment with Toxoplasma antigens and P. acnes on numbers of brain cysts. Treatment that produced high antibody titers (2 1:1,024) or activated peritoneal macrophages led to reduced numbers of Toxoplasma cysts in brains of mice 30 days after peroral challenge, although the differences did not achieve statistical significance ( Table 2 ). Treatments that produced high titers of specific antibody and activated macrophages appeared to act together to significantly (P = 0.01) reduce but not completely eliminate Toxoplasma cysts in brains 30 days after peroral challenge ( Table 2) .
Effect of treatment with Toxoplasma antigens and P. acnes on infection after peroral challenge with strain Me49. All mice became infected with T. gondii Me49, as documented by subinoculation of brain tissues. Comparisons of the numbers of T. gondii in the brains of control and experimental mice also were made by serial dilutions of brains 8 days after (Table 3) . The brains from all six controls and challenged mice infected all the recipients at a dilution greater than or equal to 1:10,000, whereas four (66%) of six mice that were treated with P. acnes and then challenged infected the recipients at a dilution greater than or equal to 1:10,000. Only two (40%) of five mice treated with Toxoplasma antigen and P. acnes which were then challenged infected the recipients at a dilution greater than or equal to 1:10,000 (Table 3 ; P < 0.05).
Effect of treatment with Toxoplasma antigens and P. acnes on prevention of congenital transmission. One hundred percent of 65 pups of control mice and 98% of 56 pups of mothers with high Toxoplasma antibody titers were infected (Table 4) . Of 59 pups of mothers with activated macrophages 85% were infected. Only 69% of 58 pups from mothers with Toxoplasma antibody and activated macrophages were infected (Table 4) . High titers of antibody alone did not protect against congenital infection. Mice treated with P. acnes delivered reduced numbers of T. gondii-infected pups, although the differences did not achieve statistical significance. Treatment that produced high titers of Toxoplasma antibody and activated macrophages provided the greatest protection against congenital transmission: the fractions of litters that were infected when delivered of mice treated with Toxoplasma antigen and P. acnes were significantly different from those of control mice and those of mice treated with Toxoplasma antigen alone (P < 0.05, using an analysis of variance). Although treatment with P. acnes and Toxoplasma antigen provided statistically significant protection of pups, compared with those in litters of the untreated and Toxoplasma antigen-treated mothers, the differences between litters treated with P. acnes and P. acnes plus Toxoplasma lysate antigens were small (P > 0.05). Therefore, the protective effect may be conferred primarily by P. acnes treatment.
DISCUSSION
Information about the effectiveness of vaccines against T. gondii is largely based on studies of parenterally immunized mice that were tested by parenteral challenge (2, 10, 21, 24) and in which protection was measured by survival. Since T. gondii causes significant illness either through recrudescence of latent organisms in immunocompromised individuals or when it is acquired congenitally, it is also of interest to study whether immune responses protect against peroral or congenital acquisition of the organism. The immune response to T. gondii is complex and involves humoral and cellular mechanisms (16; for a review, see S. D. Sharma, in D. Wyler (ed.), Modern Parasite Biology, in press). Lymphocytes and mononuclear phagocytes have been shown to be major effector cells of cell-mediated responses to T. (14) . Recent studies have shown that the L3T4 T-cell subset is responsible for antigen-specific lymphocyte transformation and that this T-cell subset is regulated by a B-cell-dependent mechanism (1) . Therefore, our studies were initiated to determine the effect of the elicitation of a T. gondii-specific humoral response and/or the activation of macrophages to inhibit or kill T. gondii on peroral acquisition and congenital transmis- (20) . This suggests that established immunity prevents transplacental transmission of T. gondii in humans (20) . Our experiments indicate that this can also be demonstrated in the mouse model. Mice with activated macrophages delivered reduced numbers of T. gondii-infected pups (although the differences did not achieve statistical significance), and treatment that produced T. gondii- specific serum antibody and activated macrophages provided significant protection against congenital transmission.
In our experiments, it is probable that activated macrophages and specific antibody contributed to the in vivo protection. Administration of Toxoplasma antigen did not enhance macrophage microbicidal capacity, and P. acnes treatment did not produce specific Toxoplasma antibody, yet each treatment alone conferred protection: the effects of Toxoplasma antigen and P. acnes treatment on peroral acquisition and congenital transmission occurred in the presence of specific antibody or activated macrophages or both. It will be of interest in future studies to determine whether these treatments also induce other cellular mechanisms which could act together with activated macrophages and antibody to limit Toxoplasma infection in vivo or result in more complex interactions. The effect of these treatments on natural killer cell activity against T. gondii has not been studied. Recently, it was demonstrated that injection of mice with P. acnes causes an initial enhancement of splenic natural killer cell activity against tumor targets followed in 11 to 15 days by a profound reduction in natural killer cell activity (4) . Toxoplasma antigens also have been found to enhance natural killer cell activity against tumor targets (23) . Natural killer cells can reduce the viability of T. gondii in vitro (7) . It would also be of interest to study the effects of enhanced hepatic (13) or splenic (23) natural killer cell activity on peroral or congenital acquisition of T. gondii. Since specific proteins of T. gondii can lead to protection (22) or immunosuppression and diminished survival (9) , it would also be of considerable interest to determine whether such characterized proteins of T. gondii and the antibody or cellular responses they elicit have differential effects on peroral acquisition or congenital transmission.
